HC Wainwright Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $3.50

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective cut by HC Wainwright from $4.00 to $3.50 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $3.16.

Adaptimmune Therapeutics Trading Down 0.8 %

ADAP stock opened at $0.59 on Thursday. The stock has a market cap of $150.02 million, a price-to-earnings ratio of -2.67 and a beta of 2.26. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.09. The company has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $1.03. Adaptimmune Therapeutics has a one year low of $0.42 and a one year high of $2.05.

Institutional Trading of Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after purchasing an additional 394,566 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics in the third quarter worth $95,000. Finally, Jane Street Group LLC grew its stake in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.